Agios Pharmaceuticals (AGIO) announced its 2026 strategic priorities and key milestones anticipated during the year. Key highlights: AQVESME U.S. commercial launch in thalassemia underway following December 2025 FDA approval; Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S. regulatory submission to follow; Company progressing early- and mid-stage pipeline in multiple high-value indications; path to profitability through the company’s existing commercial presence in thalassemia and PK deficiency, with potential to achieve over $1 billion in peak global sales
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals price target raised to $35 from $34 at BofA
- Agios Pharmaceuticals price target raised to $25 from $20 at JPMorgan
- Agios Pharma: Broad Aqvesme Label, Premium Pricing, and Manageable Safety Profile Support Buy Rating and 54.5% Upside Potential
- Agios Pharmaceuticals: Thalassemia Approval, Premium Pricing, and Manageable REMS Drive Higher Target and Undervalued Buy Thesis
- Agios: FDA Approval of Aqvesme in Thalassemia Unlocks Transformational Market Opportunity, Supporting Buy Rating and Higher Target